Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 90,030,000	$ 139,065,000
Short-term marketable securities (amortized cost of $412,282 and $214,115, respectively)	408,166,000	213,996,000
Accounts receivable, net	40,057,000	17,409,000
Inventory	14,453,000	19,263,000
Prepaid expenses and other current assets	9,440,000	13,015,000
Total current assets	562,146,000	402,748,000
Long-term assets
Property and equipment, net	83,447,000	85,262,000
Operating lease right-of-use assets	80,763,000	87,678,000
Long-term marketable securities (amortized cost of $218,163)		217,145,000
Restricted cash	2,398,000	2,138,000
Intangible assets, net	6,827,000	8,526,000
Goodwill	118,972,000	118,972,000
Other assets	2,064,000	875,000
Total assets	856,617,000	923,344,000
Current liabilities
Accounts payable	8,084,000	3,307,000
Accrued liabilities	12,424,000	9,343,000
Accrued compensation and benefits	15,935,000	15,642,000
Current portion of operating lease liabilities	9,230,000	5,055,000
Current deferred revenue	64,115,000	80,460,000
Total current liabilities	109,788,000	113,807,000
Long-term liabilities
Operating lease liabilities, less current portion	98,772,000	106,685,000
Deferred revenue, less current portion	58,599,000	98,750,000
Revenue interest liability, net	125,360,000
Total liabilities	392,519,000	319,242,000
Commitments and contingencies (Note 12)
Shareholders’ equity
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021
Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2022 and 2021; 143,105,002 and 141,393,865 shares issued and outstanding at December 31, 2022 and 2021, respectively	14,000	14,000
Additional paid-in capital	1,387,349,000	1,324,006,000
Accumulated other comprehensive loss	(4,116,000)	(1,137,000)
Accumulated deficit	(919,082,000)	(718,891,000)
Total Adaptive Biotechnologies Corporation shareholders’ equity	464,165,000	603,992,000
Noncontrolling interest	(67,000)	110,000
Total shareholders’ equity	464,098,000	604,102,000
Total liabilities and shareholders’ equity	$ 856,617,000	$ 923,344,000

Revenue interest liability, net

No definition available.

Name:	adpt_RevenueInterestLiabilityNet
Namespace Prefix:	adpt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).